Kết quả tìm kiếm - Filip Janků
- Đang hiển thị 1 - 20 kết quả của 118
- Chuyển đến trang tiếp theo
-
1
Tumor heterogeneity in the clinic: is it a real problem? Bằng Filip Janků
Được phát hành 2013Revisão -
2
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients Bằng Filip Janků
Được phát hành 2017Revisão -
3
-
4
Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) Bằng Hazem El‐Osta, Filip Janků, Razelle Kurzrock
Được phát hành 2010Artigo -
5
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening Bằng Jacob J. Adashek, Filip Janků, Razelle Kurzrock
Được phát hành 2021Revisão -
6
Erdheim-Chester Disease: Characteristics and Management Bằng Javier Muñoz, Filip Janků, Philip R. Cohen, Razelle Kurzrock
Được phát hành 2014Revisão -
7
STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia Bằng Javier Muñoz, Navjot Dhillon, Filip Janků, Stephanie S. Watowich, David S. Hong
Được phát hành 2014Revisão -
8
The mu opioid receptor: A new target for cancer therapy? Bằng Patrick A. Singleton, Jonathan Moss, Daniel D. Karp, Johnique T. Atkins, Filip Janků
Được phát hành 2015Revisão -
9
Novel Therapeutic Targets in Non-small Cell Lung Cancer Bằng Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock
Được phát hành 2011Revisão -
10
-
11
-
12
Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes Bằng Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock
Được phát hành 2010Artigo -
13
ALK fusions in the pan-cancer setting: another tumor-agnostic target? Bằng Aditya Shreenivas, Filip Janků, Mohamed A. Gouda, Hui‐Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
Được phát hành 2023Revisão -
14
-
15
-
16
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center Bằng Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock
Được phát hành 2011Artigo -
17
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers Bằng Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock
Được phát hành 2011Artigo -
18
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies Bằng John W. Moroney, Matthew Schlumbrecht, Thorunn Helgason, Robert L. Coleman, Stacy Moulder, Aung Naing, Diane C. Bodurka, Filip Janků, David S. Hong, Razelle Kurzrock
Được phát hành 2011Artigo -
19
KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors Bằng Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
Được phát hành 2012Artigo -
20
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors Bằng Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam
Được phát hành 2016Artigo
Công cụ tìm kiếm:
Các môn học liên quan
Medicine
Internal medicine
Oncology
Cancer
Biology
Cancer research
Gene
Genetics
Colorectal cancer
KRAS
Mutation
Gastroenterology
Pathology
Biochemistry
Adverse effect
PI3K/AKT/mTOR pathway
Pharmacology
Clinical trial
Bioinformatics
Breast cancer
Chemistry
Chemotherapy
Disease
Targeted therapy
Signal transduction
Mutant
Cell biology
IDH1
Kinase
Pharmacokinetics